768 860
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consultancies,
honoraria, stock ownership or options, expert testimony, royalties, or
patents filed, received, or pending), are the following: Bach has received
speaker honoraria from Cook Urology, Boston Scientific, GSK, and Richard
Wolf, participates in a trial for Ipsen, and has received fellowships and
travel grants from Lisa Laser; Drake has received speaker honoraria from
Allergan, Astellas, and Ferring. He has received grants and research
support from Allergan, Astellas, and Ferring; Gacci is a company
consultant for Bayer, Ibsa, GSK, Lilly, Pfizer, and Pierre Frabre. He
participates in trials for Bayer, Ibsa, and Lilly, and has received travel
grants and research support from Bayer, GSK, and Lilly; Gratzke is a
company consultant for Astellas Pharma, Bayer, Dendreon, Lilly,
Rottapharm-Madaus, and Recordati. He has received speaker honoraria
from AMS, Astellas Pharma, Pfizer, GSK, Steba, and Rottapharm-Madaus,
and travel grants and research support from AMS, DFG, Bayer Healthcare
Research, the EUSP, MSD, and Recordati; Maderbacher is a company
consultant for Astellas, GSK, Lilly, and Takeda, and receives speaker
honoraria from Astellas, Bo¨hringer Ingelheim, GSK, Lilly, MSD, and
Takeda. Mamoulakis is a company consultant for Astellas, GSK, and
Teleflex, and has received speaker honoraria from Elli Lilly. He
participates in trials for Astellas, Elli Lilly, Karl Storz Endoscope, and
Medivation, and has received fellowships and travel grants from Ariti,
Astellas, Boston Scientific, Cook Medical, GSK, Janssen, Karl Storz
Endoscope, Porge-Coloplast, and Takeda. Gravas has received grants or
research support from Pierre Fabre Medicament and GSK, travel grants
from Angelini Pharma Hellas, Astellas, GSK, and Pierre Fabre Medicament,
and speaker honoraria from Angelini Pharma Hellas, Pierre Fabre
Medicament, Lilly, and GSK, and is a consultant for Astellas, Pierre Fabre
Medicament, and GSK. Herrmann declares Karl Storz GmBH, honoraria,
financial support for attending symposia, financial support for educa-
tional programs, consultancy, advisory, royalties: Boston Scientific AG
honoraria, financial support for attending symposia, financial support for
educational programs,
[55_TD$DIFF]
consultancy,
[56_TD$DIFF]
advisory Board; LISA Laser OHG AG
Honoraria, financial support for attending symposia, financial support for
educational programs; Ipsen Pharma Honoraria, financial support for
attending symposia, advisory board; Bosch has received grants or
research support from GSK and Astellas, speaker honoraria from GSK,
AstraZeneca, Allergan, and FerringAG. He participates in trials for Astellas
and is a consultant for Astellas, Eli-Lilly, and Ferring AG.
Funding/Support and role of the sponsor:
None.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.06.010 .References
[1]
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminol- ogy of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78.[2]
Cornu JN, Abrams P, Chapple CR, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and man- agement–a systematic review and meta-analysis. Eur Urol 2012;62:877–90.[3]
Gulur DM, Mevcha AM, Drake MJ. Nocturia as a manifestation of systemic disease. BJU Int 2011;107:702–13.[4]
Drake MJ. Should nocturia not be called a lower urinary tract symptom? Eur Urol 2015;67:289–90.[5]
Goessaert AS, Krott L, Hoebeke P, Van de Walle J, Everaert K. Diagnosing the pathophysiologic mechanisms of nocturnal poly- uria. Eur Urol 2015;67:283–8.[6]
Marshall SD, Raskolnikov D, Blanker MH, et al. Nocturia: current levels of evidence and recommendations from the International Consultation on Male Lower Urinary Tract Symptoms. Urology 2015;85:1291–9.[7]
Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardization of terminology in nocturia: report from the standardization sub- committee of the International Continence Society. BJU Int 2002;90(Suppl 3):11–5.[8]
Cho SY, Lee KS, Kim JH, et al. Effect of combined systematized behavioral modification education program with desmopressin in patients with nocturia: a prospective, multicenter, randomized, and parallel study. Int Neurourol J 2014;18:213–20.[9]
Yee CH, SoWY, Yip SK, Wu E, Yau P, Ng CF. Effect of weight reduction on the severity of lower urinary tract symptoms in obese male patients with benign prostatic hyperplasia: a randomized con- trolled trial. Korean J Urol 2015;56:240–6.[10]
van Kerrebroeck P, Rezapour M, Cortesse A, Thuroff J, Riis A, Norgaard JP. Desmopressin in the treatment of nocturia: a dou- ble-blind, placebo-controlled study. Eur Urol 2007;52:221–9.[11]
Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double- blind placebo-controlled study in men. BJU Int 2002;89:855–62.[12]
Asplund R, Sundberg B, Bengtsson P. Oral desmopressin for noctur- nal polyuria in elderly subjects: a double-blind, placebo-controlled randomized exploratory study. BJU Int 1999;83:591–5.
[13]
Rezakhaniha B, Arianpour N, Siroosbakhat S. Efficacy of desmo- pressin in treatment of nocturia in elderly men. J Res Med Sci 2011;16:516–23.
[14]
Wang CJ, Lin YN, Huang SW, Chang CH. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperpla- sia: a double-blind, placebo controlled, randomized study. J Urol 2011;185:219–23.[15]
Weiss JP, Zinner NR, Klein BM, Norgaard JP. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a ran- domized, double-blind, placebo-controlled trial. Neurourol Urodyn 2012;31:441–7.
[16]
Weiss JP, Herschorn S, Albei CD, Van Der Meulen EA. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol 2013;190:965–72.
[17]
Yamaguchi O, Nishizawa O, Juul KV, Norgaard JP. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disinte- grating tablet in a randomized, placebo-controlled trial. BJU Int 2013;111:474–84.[18]
Cannon A, Carter PG, McConnell AA, Abrams P. Desmopressin in the treatment of nocturnal polyuria in the male. BJU Int 1999;84:20–4.
[19]
Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol 2005;4:61–8.[20]
Ceylan C, Ceylan T, Doluoglu OG, Yuksel S, Agras K. Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial. Urol J 2013;10:993–8.
[21]
Ukimura O, Kanazawa M, Fujihara A, Kamoi K, Okihara K, Miki T. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with spe- cial reference to the storage symptom: a prospective randomized study. Int J Urol 2008;15:1049–54.[22]
Eisenhardt A, Schneider T, Cruz F, Oelke M. Consistent and signifi- cant improvement of nighttime voiding frequency (nocturia) withE U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 7 5 7 – 7 6 9
768